# Phase II Study of LM-24C5

Source: https://onco.cc/trials/nct07387081/  
OnCo record `nct07387081` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of LM-24C5 in advanced solid tumours, run by LaNova Medicines Limited, now recruiting.

## Summary

Phase II Study of LM-24C5 is a phase 2 interventional study registered as NCT07387081 by LaNova Medicines Limited, with 130 participants planned, started 2025-12-15 and due to reach its primary completion in 2028-05-21. Interventions recorded: LM-24C5.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07387081
- Phase: 2
- Setting: An Open-label, Multicenter Phase II Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of LM-24C5 in Combination With Other Anti-tumor Treatment in Subjects With CEACAM5-positive Advanced Solid Tumors
- Sponsor: LaNova Medicines Limited
- Enrolled: 130

## Sources

- ClinicalTrials.gov NCT07387081: https://clinicaltrials.gov/study/NCT07387081

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [LaNova Medicines](https://onco.cc/companies/lanova-medicines/)

---
JSON: https://onco.cc/api/v1/entities/nct07387081.json